Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, April 25, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Merck & Co. Inc. Analyst Notes
On April 17, 2014, Merck & Co. Inc. (Merck) announced that its RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U) has been approval by the U.S. Food and Drug Administration (FDA). According to the Company, RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Dr. Sean Curtis, Vice President, Respiratory and Immunology, Merck Research Laboratories, said, "The FDA approval of RAGWITEK brings an important new option for allergy specialists treating adults with allergic rhinitis with or without conjunctivitis caused by short ragweed pollen." According to the Company, RAGWITEK will be available in U.S. pharmacies by the end of April 2014. The full analyst notes on Merck are available to download free of charge at:
http://www.analystsreview.com/1613-MRK-25Apr2014.pdf
Johnson & Johnson Analyst Notes
On April 15, 2014, Johnson & Johnson (Johnson & Johnson) released its Q1 2014 earnings results. The Company reported Q1 2014 sales of $18.1 billion, up 3.5% YoY, beating the Zacks consensus estimate of $17.9 billion. The rise in the Company's topline was helped mainly by 10.8% YoY increase in Pharmaceutical segment sales at $7.5 billion. During the quarter, the Consumer segment sales declined 3.2% YoY to $3.6 billion, while the Med Devices & Diagnostics segment sales remained flat at $7.1 billion. The Company's Q1 2014 net earnings of $4.7 billion, or $1.64 per diluted share, also surpassed the Zacks consensus estimate of $1.48 per share. The Company increased its earnings guidance for full-year 2014 to $5.80 - $5.90 per share. The full analyst notes on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/1613-JNJ-25Apr2014.pdf
UnitedHealth Group Inc. Analyst Notes
On April 17, 2014, UnitedHealth Group Inc. (UnitedHealth) released its Q1 2014 financial results. Hit by the newly effective ACA taxes and regulatory provisions and sequestration cuts to Medicare, the Company reported a decline in its net income at $1.1 billion, or $1.10 per diluted share, from $1.2 billion, or $1.16 billion per diluted share, in Q1 2013. UnitedHealth's revenues during the quarter increased 4.5% YoY to $31.7 billion, helped by broad-based growth across its Optum health services platform. Reacting to the drop in bottom-line, the Company's stock fell 3.08% to close at $75.78 on April 17, 2014. Management continues to forecast 5% growth in consolidated revenues in full-year 2014 - to a range of $128 billion to $129 billion - and net earnings in the range of $5.40 to $5.60 per share. The full analyst notes on UnitedHealth are available to download free of charge at:
http://www.analystsreview.com/1613-UNH-25Apr2014.pdf
Celgene Corporation Analyst Notes
On April 22, 2014, Shares in Celgene Corporation (Celgene) moved up 1.95% to end the trading session at $146.64, extending its gain from previous trading session. The rise in stock of Celgene was in line with the overall strength in the healthcare sector with the S&P healthcare index gaining the most among 10 major S&P sectors. Shares in Celgene opened the session at $144.70 and fluctuated between $144.10 and $147.50. In the last one month, the stock has moved up 1.55%, compared to the Nasdaq Composite which declined 2.70% over the same period. The full analyst notes on Celgene are available to download free of charge at:
http://www.analystsreview.com/1613-CELG-25Apr2014.pdf
GW Pharmaceuticals PLC Analyst Notes
On April 22, 2014, GW Pharmaceuticals plc's (GW) stock rallied 32.19% to end the trading session at $60.86. According to an article on NASDAQ, the stock was surging as Morgan Stanley initiated coverage on Company with an "Overweight" rating and a price target of $103 per share. The stock of GW opened the session at $ 50.10 and oscillated in the range of $50.00 - $65.97. A total of 6.78 million shares were traded, significantly higher than the previous day trading volume 0.29 million shares. Over the past three trading sessions, the stock has increased 36.34% outperforming the NASDAQ Composite, which rose 1.84% over the same time period. The full analyst notes on GW are available to download free of charge at:
http://www.analystsreview.com/1613-GWPH-25Apr2014.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystsreview.com/
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article